A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Clinical trial NCT06208150 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06208150
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-22
- Primary completion
- 2026-04-01
- Enrollment
- 838
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.